ID: ALA3244493

Max Phase: Preclinical

Molecular Formula: C10H13ClN5O7P

Molecular Weight: 381.67

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C10H13ClN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6-,9-/m1/s1

Standard InChI Key:  FXXRIUZMLRLFKP-UUOKFMHZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 381.67

Molecular Weight (Monoisotopic): 381.0241

AlogP: -1.21

#Rotatable Bonds: 4

Polar Surface Area: 186.07

Molecular Species: ACID

HBA: 10

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 1.18

CX Basic pKa: 2.23

CX LogP: -2.54

CX LogD: -4.84

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.32

Np Likeness Score: 1.06

References

1. Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, Boyer JL, Harden TK, Jacobson KA..  (2002)  Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.,  45  (10): [PMID:11985476] [10.1021/jm010538v]

2. Hai TT, Picker D, Abo M, Hampton A..  (1982)  Species- or isozyme-specific enzyme inhibitors. 7. Selective effects in inhibitions of rat adenylate kinase isozymes by adenosine 5'-phosphate derivatives.,  25  (7): [PMID:6286970] [10.1021/jm00349a008]

3. Gough GR, Nobbs DM, Middleton JC, Penglis-Caredes F, Maguire MH..  (1978)  New inhibitors of platelet aggregation. 5'-Phosphate, 5'-phosphorothioate, and 5'-O-sulfamoyl derivatives of 2-substituted adenosine analogues.,  21  (6): [PMID:671448] [10.1021/jm00204a004]

Source

Source(1):

• Scientific Literature